New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies (Q34990105)

5 August 2017

1 reference

title

New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies (English)

1 reference

5 August 2017

1 reference

Ghulam Saydain

1

1 reference

5 August 2017

Liziamma George

series ordinal

2

1 reference

5 August 2017

Suhail Raoof

series ordinal

3

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

published in

Critical Care Clinics

1 reference

5 August 2017

volume

18

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

957-975

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Anti-cytokine therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Monoclonal antibodies and other biologic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of Thrombotic Thrombocytopenic Purpura with Plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Therapeutic Plasma Exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Influence of Plasma Exchange on Serum Levels of Cytokines and Adhesion Molecules in ANCA-Positive Renal Vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Nephrotoxicity of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Frequency of immediate adverse effects associated with therapeutic apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Introduction to the third special issue: clinical applications of therapeutic apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Reversal of Impaired Splenic Function in Patients with Nephritis or Vasculitis (or Both) by Plasma Exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Therapeutic plasma exchange: an update from the Canadian Apheresis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

An overview of current management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Lymphapheresis in rheumatoid arthritis. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Effect of lymphoplasmapheresis on clinical indices and T cell subsets in rheumatoid arthritis. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Pulmonary hypertension secondary to serum hyperviscosity in a patient with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Limited plasmapheresis in rheumatoid arthritis with vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Rheumatoid vasculitis: diagnostic and therapeutic decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Rheumatoid vasculitis: experience with 13 patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Rheumatoid hyperviscosity: analysis of a patient with intermediate complexes that block other autoantibodies and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasmapheresis in the management of acute systemic lupus erythematosus?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Randomised trial of plasma exchange in mild systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Desperate diseases and plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The central nervous system in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Apheresis for lupus erythematosus: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of hemorrhagic lupus pneumonitis with plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Alveolar hemorrhage in systemic lupus erythematosus: presentation and management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Cerebral lupus erythematosus responding to plasmaphaeresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Neuropsychiatric Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Plasmapheresis treatment of central retinal vein occlusion in a young adult

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The use of intravenous immune globulin in immunodeficiency diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Intravenous immunoglobulin treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of systemic vasculitis with pooled intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Hemolytic anemia following intravenous gamma globulin administration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Acute renal failure associated with immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Biologic therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Potential biologic agents for treating rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immune regulation by CD40 and its ligand GP39.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Clinical and pharmacological experience with LJP-394.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

Gene therapy for autoimmune disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2802%2900028-3

7 January 2021

10.1016/S0749-0704(02)00028-3

Identifiers

DOI

1 reference

5 August 2017

1 reference